Bio-Path Holdings Stock-Based Compensation Growth & History (BPTH)

Bio-Path Holdings's stock-based compensation was $566,000 for fiscal 2024.

View full Bio-Path Holdings company overview

Bio-Path Holdings annual stock-based compensation history

Bio-Path Holdings annual stock-based compensation

Fiscal yearPeriod endedStock-based compensationChangeGrowth
20242024-12-31$566,000−$168,000−22.89%
20232023-12-31$734,000−$117,000−13.75%
20222022-12-31$851,000$30,000+3.65%
20212021-12-31$821,000$244,000+42.29%
20202020-12-31$577,000−$107,000−15.64%
20192019-12-31$684,000$130,000+23.47%
20182018-12-31$554,000−$239,000−30.14%
20172017-12-31$793,000$9,000+1.15%
20162016-12-31$784,000$415,000+112.47%
20152015-12-31$369,000−$35,000−8.66%
20142014-12-31$404,000−$300,480−42.65%
20132013-12-31$704,480$641,095+1011.43%
20122012-12-31$63,385−$319,533−83.45%
20112011-12-31$382,918−$94,438−19.78%
20102010-12-31$477,356

Bio-Path Holdings stock-based compensation trends

Over the last five fiscal years, Bio-Path Holdings's stock-based compensation decreased from $684,000 to $566,000, a change of −$118,000. The latest reported quarter, Q1 2026, shows $5,000.

About the metric

What stock-based compensation means

Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.

Calculation and source

SEC-reported stock-based compensation

TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Bio-Path Holdings source filings ↗

Community posts

It’s quiet here.

No posts about BPTH yet. Start the conversation.

Write the first post